Results 201 to 210 of about 863,493 (265)

Integrated PANoptosis Profiling Identifies Immunosuppressive Subtypes and a Prognostic Signature With Functional Validation of MLKL in Glioblastoma

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The prognosis of glioblastoma (GBM) remains highly unfavorable, largely due to high tumor heterogeneity and an immunosuppressive microenvironment. However, the functional role of PANoptosis in this context is poorly understood. Methods Patients were stratified via K‐means clustering. A risk score model was constructed using prognosis‐
Langfei Tian, Minghui Zhao, Yuanbo Hu, Kaiyue Wang, Haiguang Liu, Zetong Bai, Kebin Zheng   +6 more
wiley   +1 more source

Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels. [PDF]

Blood Adv
Banerjee R, Mohan M, Rejeski K, Puliafito BR, Cirstea DD, Kaur G, Midha S, McCaughan GJ, Kumar NM, Mehra N, Bagal B, Raje NS.   +11 more
europepmc   +1 more source

Disease Course After Anti‐CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto, Dariia Kliushnikova, Richard Friedrich Radlberger, Sinan Yasaroglu, Tobias Moser, Andrea Harrer, Kitty Kratzer, Wolfgang Hitzl, Christiane Gradl, Martin Schmidauer, Patrick Roth, Harald Hegen, Peter Wipfler   +12 more
wiley   +1 more source

Intracerebral Hemorrhage Induces Monocyte TNF Signaling in Patients That Is Suppressed by BAF312

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Intracerebral hemorrhage (ICH) causes high morbidity and mortality, with neurotoxic inflammation driven by infiltrating monocytes. This study is an in‐depth longitudinal examination of the immune response during the first week of ICH in the presence and absence of the immunomodulatory drug BAF312 (Siponimod).
Jonathan Howard DeLong, Sebastian Díaz‐Pérez, Kevin Navin Sheth, Jang‐Ho Cha, C. J. Malanga, Patricia G. M. Wagner, Nicole Pezous, Aurelie Hanin, Kyle B. Walsh, H. E. Hinson, Lauren Hachmann Sansing   +10 more
wiley   +1 more source

Case Report: autologous stem cell boost enables hematopoietic recovery after severe cytopenia induced by BCMA-targeted bispecific antibody therapy in multiple myeloma. [PDF]

Front Oncol
Akiyama H, Kakiuchi S, Sakamoto A, Tomigaki N, Fujioka S, Harima I, Niwa R, Takagi I, Kozuki Y, Miyata Y, Yoshihara K, Yoshihara S, Iwata N.   +12 more
europepmc   +1 more source

Bispecific antibody therapy-associated opportunistic infections: cytomegalovirus retinitis and chronic salmonellosis in a non-HIV patient. [PDF]

Haematologica
Cochran-Perez MR, Sharma P, Delisle JS, Schlesinger M, Rao H, Trias J, Keller M.   +6 more
europepmc   +1 more source

Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma. [PDF]

Pediatr Blood Cancer
Wei W, Fader ME, Kushner BH, Cardenas FI, Kramer K, Basu E, Modak S.   +6 more
europepmc   +1 more source

Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma. [PDF]

Blood Adv
Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, Holtick U, Boyadzhiev H, Melchardt T, Hölscher A, Schultze-Florey C, Abdelhafez A, Velazquez GF, Ossami Saidy A, Lesan V, Schnetzke U, Kerkhoff A, Bacher U, Ghandili S, Aydilek E, Gebauer N, Weber T, Wulf G, Glass B, Thurner L, Heidel FH, Schmid C, Viardot A, Hänel M, Dietrich S, Pabst T, Ayuk F, von Tresckow B, Chapuy B, Pott C, Müller F, Lenz G.   +36 more
europepmc   +1 more source

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy

Altaf M, Nel C, Tipoe T, Edgar J, Zacharopoulou P, Srai D, Knight C, Lee M, Cherrill L, Falaschetti E, Ogbe A, Fletcher S, Box H, Elliott T, Kinloch S, Fox J, Clarke A, Pett S, Collins S, Balachandran M, Topping K, Terry L, Seaton K, Tomaras G, Uriel A, Orkin C, Ring K, Whitlock G, Boffito M, Sutherland R, Søgaard OS, Gunst JD, Brown H, Robinson N, Lindegard G, Goulder P, Taylor G, Caskey M, Nussenzweig M, Fidler S, Frater J, The RIO Study Team.   +41 more
europepmc   +1 more source